T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Financial Institutions
FISI
$825M
| $367K | ﹤0.01% |
11,765
+1,232
| +12% | +$36.3K |
|
2527
Ichor Holdings
ICHR
$2.67B
| $366K | ﹤0.01% |
19,848
+1,817
| +10% | +$33.7K |
|
|
SVC
2528
Service Properties Trust
SVC
$1.06B
| $366K | ﹤0.01% |
39,761
+2,554
| +7% | +$25.7K |
|
2529
EVgo
EVGO
$519M
| $365K | ﹤0.01% |
125,170
+9,132
| +8% | +$33.2K |
|
2530
Forum Energy Technologies
FET
$927M
| $365K | ﹤0.01% |
9,868
-1,574
| -14% | -$48.8K |
|
2531
Gray Television
GTN
$520M
| $365K | ﹤0.01% |
75,336
-47,470
| -39% | -$232K |
|
|
OS
2532
DELISTED
OneStream Inc
OS
| $365K | ﹤0.01% |
19,855
+2,700
| +16% | +$51.5K |
|
2533
TFS Financial
TFSL
$4.93B
| $364K | ﹤0.01% |
27,156
+1,401
| +5% | +$19.2K |
|
|
TRUE
2534
DELISTED
TrueCar
TRUE
| $364K | ﹤0.01% |
160,683
| – | – |
|
|
STRZ
2535
Starz Entertainment Corp
STRZ
$479M
| $364K | ﹤0.01% |
31,039
+2,900
| +10% | +$33.2K |
|
|
CTLP
2536
DELISTED
Cantaloupe
CTLP
| $363K | ﹤0.01% |
34,177
+2,572
| +8% | +$27.3K |
|
2537
Prime Medicine
PRME
$575M
| $363K | ﹤0.01% |
104,553
+30,051
| +40% | +$134K |
|
2538
Aquestive Therapeutics
AQST
$533M
| $362K | ﹤0.01% |
55,951
+10,865
| +24% | +$67.7K |
|
2539
Genco Shipping & Trading
GNK
$1.13B
| $361K | ﹤0.01% |
19,534
+1,599
| +9% | +$28.1K |
|
|
NIQ
2540
NIQ Global Intelligence PLC
NIQ
$4.97B
| $361K | ﹤0.01% |
21,884
+1,815
| +9% | +$26.6K |
|
|
SEMR
2541
DELISTED
Semrush
SEMR
| $359K | ﹤0.01% |
30,127
| – | – |
|
|
GRDN
2542
Guardian Pharmacy Services
GRDN
$2.44B
| $358K | ﹤0.01% |
11,885
+1,409
| +13% | +$39.9K |
|
2543
Acco Brands
ACCO
$399M
| $357K | ﹤0.01% |
95,615
-42,900
| -31% | -$159K |
|
2544
Mid Penn Bancorp
MPB
$971M
| $357K | ﹤0.01% |
11,502
+842
| +8% | +$24.9K |
|
|
OLP
2545
One Liberty Properties
OLP
$537M
| $354K | ﹤0.01% |
17,420
+1,454
| +9% | +$30.1K |
|
2546
Capital City Bank Group
CCBG
$898M
| $353K | ﹤0.01% |
8,291
+939
| +13% | +$39.1K |
|
2547
Cytek Biosciences
CTKB
$636M
| $353K | ﹤0.01% |
69,793
+7,658
| +12% | +$35.6K |
|
2548
Grid Dynamics Holdings
GDYN
$644M
| $353K | ﹤0.01% |
39,083
-10,722
| -22% | -$92.9K |
|
2549
BlackSky Technology
BKSY
$1.27B
| $352K | ﹤0.01% |
18,747
+2,088
| +13% | +$42.6K |
|
2550
Gossamer Bio
GOSS
$83.3M
| $351K | ﹤0.01% |
113,138
+12,480
| +12% | +$35.6K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.